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Established clinico–pathological factors can place patients with breast cancer into good and poor prognostic categories, but even
within these groups behaviour and response to treatment can differ. This study examined the value of cell cycle and apoptotic
regulatory proteins in predicting behaviour in a poor prognostic group. A total of 165 patients, all of whom had died of breast cancer
with duration of survival 12–127 months, median 38 months, were examined using immunohistochemistry for proliferation,
apoptosis, p53, phosphorylated p53, p21, checkpoint kinase 2 (Chk2), bcl-2, bax, survivin and XIAP. All had received chemotherapy
and/or hormonal therapy and were predominantly T2, node positive, grade III with only half oestrogen-receptor (ER) positive. High
proliferation, phosphorylated p53, Chk2 and survivin expression correlated with grade III and lack of ER, whereas low proliferation,
p21 and bcl-2 related to better grade and presence of ER. On univariate analysis grade, proliferation, phosphorylated p53, bcl-2, ER
and survivin related to duration of survival. In multivariate analysis, grade (P¼0.001) and survivin (P¼0.005) were independent
prognostic factors, grade III and presence of survivin relating to shorter survival. The latter was particularly for those patients receiving
neoadjuvant therapy and adjuvant chemo- and hormonal therapy. The presence of the inhibitor of apoptosis protein survivin is a
highly significant independent predictor of shorter duration of survival of patients with poor prognostic features, and merits
investigation as a marker in other prognostic groups.
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It is well recognised that breast cancer is a heterogeneous disease.
Although there has been an improvement in outcome owing to
better early detection and the use of adjuvant therapy (Early Breast
Cancer Trialists Collaborative Group, 2005), behaviour is variable.
For the management of individual patients there is a need to have
markers that can identify those cancers likely to have a better or a
worse prognosis (prognostic) and also aid the selection of
appropriate therapy (predictive) (Gelber et al, 2003; Hayes,
2003). Clinico-pathological factors such as tumour size, node
status and tumour grade are acknowledged important prognostic
factors (Carter et al, 1989; Elston and Ellis, 1991; Henson et al,
1991; Galea et al, 1992; Gebauer et al, 2002). Oestrogen receptor
(ER) status has been used for many years for the selection of those
patients who are more likely to benefit from hormone treatment,
either for metastatic disease (Elledge et al, 2000) or as adjuvant
therapy (Harvey et al, 1999). There are no comparable predictive
markers for identifying those patients for whom chemotherapy will
or will not be effective.
The TP53 gene has important roles in cell cycle regulation and
apoptosis following DNA damage (Harris, 2000; Vousden and Lu,
2002). The effect of several chemotherapeutic drugs may be
mediated through DNA damage and induction of apoptosis
(Gewirtz, 2000), and therefore alterations to TP53 and hence p53
protein function could result in relative resistance to these agents.
Studies assessing either immunohistochemically detectable p53
and/or TP53 mutations in breast cancers and response to
chemotherapy differ in their findings as to their value as predictors
(Bergh et al, 1995; Elledge et al, 1995; Stal et al, 1995; Aas et al,
1996; Thor et al, 1998; Berns et al, 2000; Rahko et al, 2003).
However, as apoptosis plays a major role in treatment response,
analysis of other apoptotic regulatory gene products, as well as
p53, may give additional information.
The bcl-2 family of apoptotic proteins comprise anti-apoptotic
proteins such as bcl-2 and bcl-xl, and pro-apoptotic proteins such
as bax, and these form heterodimers (Reed, 2000). P53 promotes
apoptosis by inducing bax, so increasing the ratio of pro- to anti-
apoptotic proteins (Haupt et al, 2003). The presence of bcl-2 in
breast cancers positively correlates with ER (Gee et al, 1994). In
vitro drug response assays showed Bcl-2-negative breast cancers to
be more susceptible to chemotherapeutic drugs than bcl-2-positive
(Yang et al, 2000), but immunohistochemical studies of breast
cancers have been less conclusive (Krajewski et al, 1995). Although
one study found reduced expression of bax to be associated with a
poor response to chemotherapy in patients with metastatic breast
cancer (Daidone et al, 1999a), others have not (Daidone et al,
1999b; Sjo ¨strum et al, 2002). The inhibitors of apoptotic proteins
are a more recently described family of proteins that includes
survivin and XIAP, which act by direct inhibition of caspases
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s(Deveraux and Reed, 1999). Survivin expression is negatively
regulated by wild-type p53 and it participates in p53-dependent
apoptotic pathways (Mirza et al, 2002). One study has shown that
the presence of survivin in breast cancer relates to apoptosis but
not prognosis (Tanaka et al, 2000). Another found it to relate to
poor prognosis (Span et al, 2004) and one (Kennedy et al, 2003) to
a better prognosis. There are little data about XIAP in breast.
Parton et al (2002) reported that XIAP was not a predictive marker
of response to chemotherapy, but the small sample size may not
have been representative.
P53 is also involved in cell cycle arrest and induces p21
waf1 in
response to DNA-damaging agents (el-Deiry et al, 1994). p21
blocks progression of the cell cycle at G1/S and is involved in G2/M
phase arrest (Dulic et al, 1998). Caffo et al (1996) concluded from a
study of patients who received adjuvant therapy and had long-term
follow-up that p21 /p53þ tumours had the worst prognosis and
that this pattern of expression may be of relevance for therapeutic
response. However, Sjostrum et al (2000) found no relationship
between expression of p21 and p53 and response to chemotherapy
in advanced disease. Checkpoint kinase 2 is a cell cycle checkpoint
protein that can regulate p53 by phosphorylation in response to
DNA double-strand breaks (Bartok and Lukas, 2004). Loss of
function of Chk2, by downregulation of expression and p53 by
mutation, has been reported in a proportion of sporadic breast
cancers (Sullivan et al, 2002). A recent immunohistochemical
study showed reduction of Chk2 expression to relate to larger
tumour size but not to other parameters (Kilpivaara et al, 2005).
Even within patients with cancers having similar poor
prognostic features there can be differences in duration of survival.
Our hypothesis was that p53, apoptotic and cell cycle regulatory
proteins in combination would provide greater information about
breast cancer behaviour. This was tested in a group of patients who
had received chemotherapy and/or endocrine therapy, who had a
higher incidence of poor prognostic features at presentation and
who had died of the disease. Immunohistochemistry was the
method of choice, as this tool is widely available and used clinically
for predictive testing.
MATERIALS AND METHODS
Patients
A total of 165 patients diagnosed with breast cancer at University
Hospitals of Leicester NHS Trust between 1991 and 2002 were
studied and all had died from the disease. A breast cancer patient
database, established by Miss A Stotter, was used to identify
patients’ complete data for all patients, treated by two surgeons.
The complete data was available for 1991 and 1997–2002 and the
incomplete data was available for 1992–1996. All patients who had
received chemotherapy and for which sufficient tissue was
available were included. Patients receiving only tamoxifen were
restricted to those 70 years and under and were selected to
represent a wide range of survival duration. All information on
treatment and cause of death had been validated. A total of 18
patients had received neoadjuvant chemotherapy before surgery,
with nine having subsequent adjuvant hormonal therapy. All had
residual tumour present in the subsequent mastectomy, with eight
having a reduction in tumour size. A total of 147 patients had
either mastectomy or wide local excision with axillary surgery
followed by adjuvant therapy: Eighteen chemotherapy alone; 70
chemotherapy followed by Tamoxifen, 59 Tamoxifen alone.
Chemotherapy was cyclophosphamide, adriamycin and fluoro-
urocil or cyclophosphamide, methotrexate and fluorourocil.
Patient ages at diagnosis ranged from 22 to 70 years, median 53
years. For analysis they were grouped as 22–48 years (premeno-
pausal), 49–56 years (perimenopausal) and 57–70 years (post-
menopausal). Survival was from 12 to 127 months with median for
the whole group of 38 months. Median survival for treatment
groups are shown in Table 1.
Table 1 Treatment regime
Neo Adjuvant Adjuvant Chemo Adjuvant Chemo+Hormonal Hormonal Total
Type No (%) No (%) No (%) No (%) No (%)
IDC 18 (100) 18 (100) 63 (90) 58 (98.3) 157 (92.2)
ILC 0 0 7 (10) 0 7 (42)
Others 0 0 0 1 (17) 1 (0.6)
Size
o20mm 5 (25.5) 4 (2.2) 12 (7.9) 20 (33.9) 40 (24.2)
20–50mm 12 (67.0) 13 (72.2) 51 (76.1) 36 (61.0) 112 (67.8)
450mm 1 (5.5) 1 (5.6) 4 (6.0) 3 (5.1) 9 (5.4)
Grade
I+II 2 (11.1) 1 (5.6) 14 (20.3) 24 (40.7) 41 (25.0)
III 16 (88.9) 17 (94.4) 55 (79.7) 35 (59.3) 123 (75.0)
Lymph node
Neg 4 (23.5) 5 (27.8) 7 (10.3) 26 (44.8) 42 (26.0)
1–3 6 (35.3) 7 (38.9) 24 (35.3) 19 (32.8) 56 (34.7)
43 7 (41.2) 6 (33.3) 37 (54.4) 13 (22.4) 63 (39.1)
ER
Neg 9 (50.0) 8 (44.4) 33 (47.8) 30 (50.8) 80 (48.7)
Pos 9 (50.0) 10 (55.6) 36 (52.2) 29 (49.2) 84 (51.2)
Age
22–48 11 15 25 2 53
49–56 3 2 27 19 51
57–70 4 1 18 38 61
Duration of survival median
(months)
32 43 33 56 38
IDC¼invasive ductal carcinoma; ILC¼ invasive lobular carcinoma
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All tissues relating to the patients were then identified from the
files of the histopathology department, University Hospitals of
Leicester NHS Trust. For those patients receiving neoadjuvant
chemotherapy needle core biopsies were available for six and these
were used for analysis, as well as the surgical material. All surgical
specimens had been received fresh, sliced and fixed for 24h in
4% formaldehyde in saline. Blocks had been selected by the
pathologist, processed through graded alcohols and xylene and
embedded in paraffin wax.
Information was available from pathology reports for tumour
size and lymph node status. All tumours were classified and graded
by RA Walker using NHS Breast Screening Programme pathology
reporting guidelines (NHSBSP, 2005). Oestrogen receptor-a status
and HER-2 status was assessed using immunohistochemistry, and
reported by RA Walker (Walker et al, 1996). The research project
was approved by Leicestershire Research Ethics Committee (Ref
7117).
Antibodies
p53: D07 mouse monoclonal antibody specific for human p53
protein wild-type and mutant forms; NCL-p53-PHOS mouse
monoclonal antibody that detects human p53 protein phosphory-
lated at Ser
392 (both Novocastra, Newcastle, UK).
Bax polyclonal rabbit anti-human bax antiserum, raised against
amino acids 43–61 (Dako, Ely, UK) polyclonal rabbit anti-human
bax antiserum raised against amino acids 150–165 (Oncogene,
Cambridge, USA)
bcl-2: NCL-bcl-2 mouse monoclonal antibody (Novocastra, UK).
bcl-2 Ab-1 mouse monoclonal antibody raised against amino acids
41–54 (Oncogene, Newcastle).
p21
waf1: NCL-WAF1 mouse monoclonal antibody raised against
full-length p21 (Novocastra, UK).
Chk2: NCL-Chk2 mouse monoclonal antibody raised against
full-length Chk2 protein (Novocastra, UK).
Ki67: MIB1 mouse monoclonal antibody raised against recom-
binant Ki-67 (Novocastra, UK).
Survivin: Ab469 rabbit polyclonal antiserum raised against full-
length human survivin protein (Abcam Ltd, Cambridge, UK)
XIAP: Goat polyclonal antiserum raised against amino acids
1–497 of human XIAP (R&D, Abingdon, UK).
M30: Cyto DEATH mouse monoclonal antibody against caspase
cleaved cytokeratin 18 (Roche, Lewes, UK)
Secondary reagents: Biotinylated anti-mouse, rabbit and goat
immunoglobulin antibodies, streptavidin–biotin complex (all
DAKO, UK); peroxidase-labelled anti-rabbit and mouse immuno-
globulin antibodies (Amersham, UK); peroxidase labelled anti-goat
immunoglobulin antibody (Calbiochem, Nottingham, UK)
Immunohistochemistry
Sections were put onto Vectabond (Vector, Peterborough, UK)
oated glass slides and dried. Endogenous peroxidase was blocked
with 2% hydrogen peroxide in water for 10min, apart from
sections to be stained for survivin and XIAP. Antigen retrieval was
in 0.2 M citrate buffer (pH 6.0) with pressure cooking for 4min for
XIAP, 2min followed by 2min for survivin and 2min for all other
antigens.
Primary antibodies were applied for 18h at 41C. Optimised
dilutions were: p53 D07 1:50; p53 PHOS 1.25; p21
waf1 1:20; ChK2
1:40; bcl-2 (Novocastra) 1:80; bax (DAKO) 1:50; MIB-1 1:100;
M30 1:200; survivin 1:400; XIAP 1:800. All dilutions and washes
were in Tris-buffered saline (pH 7.6) apart from for M30, which
was phosphate-buffered saline with 1% bovine serum albumin and
0.1% Tween 20. Appropriate biotinylated secondary antibodies
were applied for 30min at room temperature followed by
streptavidin–biotin–peroxidase complex. Peroxidase was loca-
lised using diaminobenzidine, with counterstaining with Mayers
haematoxyin. Negative controls were omission of primary anti-
body. A known positive control was used with each batch of
staining.
For all nuclear staining the number of positive cells were
counted in 1000 cells in five high-power fields (hpf) and
percentage derived. For M30 the number of positive cells in
10hpf was also counted. Cut-off points were: p53 and p53 PHOS –
moderate or strong staining X20% cells ¼ positive; p21
waf1 X5%
cells staining ¼ positive; Chk2 X20% cells staining ¼ positive;
MIB1o20% cells staining, low proliferation index, X20%, high
proliferation index.
For bcl-2 the percentage of positive cells was determined as 0
(0–4%), 1 (5–25%), 2 (26–50%), 3 (51–75%), 4 (76–100%) and
combined with intensity 1 (faint), 2 (moderate), 3 (strong) relative
to lymphocytes. Score of 0–2 was considered negative.
For bax staining, intensity was assessed as negative, faint,
moderate or strong, with moderate and strong classed as positive.
Survivin was assessed in 5hpf. Nuclear staining was scored as 0
(o5%), 1 (5–20%), 2 (21–50%), 3 (X50%), cytoplasmic as 0
(negative or faint), 1 (moderate), 2 (strong) then scores were
combined with p1 being considered negative (33). XIAP was
assessed for intensity as 1 (negative or faint), 2 moderate, 3
(strong), with 2 and 3 being positive.
Statistics
SPSS version 12.0 for Windows was used and data variables were
entered either as continuous or as grouping variables. w
2 test was
used to compare two or more grouping variables. t-test was used to
compare two groups against a continuous variable and one-way
analysis of variance for three or more groups against a continuous
variable. Kruskall–Wallis test was used for nonparametic data.
Log rank Kaplan–Meier test was employed to assess relationships
to duration of survival and Cox regression analysis was used to
determine strongest predictive factors.
RESULTS
Clinico–pathological parameters, ER and HER-2
The distribution of duration of survival, age of patient, tumour
type, size, node status and grade in relation to the different
treatment groups are shown in Table 1. There was a higher
frequency of postmenopausal patients receiving adjuvant hormo-
nal therapy. The majority of cases were infiltrating ductal
carcinoma NST with three quarters being T2 or greater, node
positive and grade III.
Over half of the cancers were ER-positive. There was a
significant correlation with grade, with a higher frequency of
grade III cancers being negative (Po0.0001). About 25% of cases
were HER-2-positive. There was an inverse correlation with ER
status (P¼0.01), but no relationship to tumour size, node status or
grade.
Proliferation and cell cycle proteins
A high proliferation index (X20% cells staining for Ki-67) was
found in 58.2% of cancers, with a significant correlation between
high index and grade III (Po0.0001) but not with other clinico–
pathological parameters. There was an inverse correlation with ER
(P¼0.001).
Staining for p21
waf 1 was predominantly nuclear and only this
was assessed. A total of 27.3% of cancers were positive with a X5%
cutoff. Grade III tumours were more likely to be negative (96/123)
(P¼0.015). There was a correlation between the presence of
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waf 1 and ER (P¼0.015). There was no relationship with
proliferation.
ChK-2 protein was detected in X20% of tumour cells in 69.7%
of cancers and showed a significant correlation with grade III
cancers (P¼0.003) and high proliferation (P¼0.005). There was
an inverse relationship with ER (P¼0.012).
p53
p53 protein was detected in 62/165 breast cancers (37.6%) and
phosphospecific p53 (phosphorylated at Ser
392) in 22.4%. There
was a strong correlation (Po0.0001) between them, with all
phosphospecific p53 cancers being positive with the D0–7
antibody. The presence of phosphospecific p53 correlated with
grade III (P¼0.002) but there were no other correlations
with clinico–pathological parameters for p53 or phospho-
specific p53. There was an inverse relationship between the
presence of phosphospecific p53 and ER (Po0.0001), but no
relationship with HER-2. Carcinomas with detectable cp53 and
phosphospecific p53 were more likely to have a high proliferation
index (P¼0.001).
Apoptosis and apoptotic proteins
Cells in early apoptosis were characterised by cytoplasmic staining
with M30 and those in advanced stages were shrunken with dark
staining cytoplasm. When the percentage of apoptotic cells was
calculated, there were 55% of tumours with o1%, 24% with 1–2%
and 21% with 42%. For assessment of 10hpf there were 37% of
cancers with o10, 33% with 10–20 and 30% with 420. There was
no correlation between apoptotic index and any clinico–patholo-
gical parameter, ER, HER-2, p53, cell cycle protein or apoptotic
protein.
Nearly half of the cancers (49.7%) were bcl-2-positive. There was
a significant correlation between lack of bcl-2 and grade III
(Po0.0001) and the presence of bcl-2 and ER (Po0.0001). Bcl-2-
positive carcinomas were more likely to have lower proliferation
(P¼0.001). There was a weak association between lack of bcl-2
and presence of HER-2 (P¼0.05).
Homogenous cytoplasmic staining of varying intensity was seen
for bax, with 91.0% of cases considered positive. There were no
correlations with clinico–pathological parameters, ER or HER-2.
Survivin was detected in cancer cells either in the nucleus,
nucleus and cytoplasm or cytoplasm, with the combined pattern of
staining predominating. Staining of both components was assessed
and combined. A total of 55.2% cancers were considered positive.
There was a significant correlation between the presence of
survivin and grade III (Po0.0001) and high proliferation (Ki-67)
(Po0.0001) with an inverse correlation with ER (Po0.0001). There
was a weaker correlation between the presence of survivin and
HER-2 positivity (P¼0.02).
XIAP was detected as homogenous cytoplasmic staining with
variation in intensity. Those cases with moderate or strong
staining were considered positive (89.7%) but there were no
correlations with clinico–pathological parameters, ER and HER-2.
Correlations between markers
Table 2 summarises those markers for which there were significant
correlations. The main findings were the positive correlations
between p53 and the IAP family members and the inverse
relationships between bcl-2 and p53 and bcl-2 and survivin.
Relationships to survival
This was considered for the tumours overall and in relation to the
treatment received.
There was a significant correlation between duration of
survival and tumour grade for patients receiving adjuvant
treatment (Po0.0001), with grade III tumours having a shorter
duration of survival. Within the group receiving hormone
therapy alone, smaller size was associated with longer survival
(P¼0.005), but overall size did not relate to duration of
survival and neither did node status. The presence of ER was
associated with longer duration of survival but only for the group
receiving adjuvant hormonal treatment alone (Po0.0001). There
was no relationship between HER-2 status and duration of
survival.
In univariate analysis the factors that related to duration of
survival overall were overall tumour grade (Pp0.0001), ER
(Pp0.001), proliferation (P¼0.001), phosphorylated p53
(Pp0.0001), bcl-2 (P¼0.01) and survivin (Pp0.0001). For those
receiving neoadjuvant chemotherapy the presence of survivin
related to shorter duration of survival (24 vs 48 months for
negative cases) (Pp0.0001). In the adjuvant therapy group grade
was significant with grade III cancers being associated with a
shorter duration of survival. Smaller size related to longer duration
of survival for those receiving hormonal therapy (P¼0.005) but
size had no effect on other groups. This was similar for ER, bcl-2
and p21, where presence related to longer duration only for the
group receiving adjuvant hormonal treatment (Po0.0001, 0.039
and 0.014, respectively). Those patients whose cancers were
positive for phosphorylated p53 and who received either adjuvant
hormonal or adjuvant chemo-plus hormonal therapy had a
significantly shorter duration of survival (P¼0.003 and 0.026
respectively). The presence of survivin related to shorter duration
of survival (32 months in comparison to 55 months for those
negative) for the group receiving adjuvant chemotherapy and
hormonal therapy (Pp0.0001).
A Cox regression model analysis of the factors found on
univariate analysis to be associated with duration of survival
showed that overall tumour grade and survivin were the most
significant (Table 3). When this was undertaken in relation to
treatment received, survivin was a significant factor for the
neoadjuvant and adjuvant chemotherapy and hormonal therapy
groups and ER for the adjuvant hormonal therapy group.
DISCUSSION
The aim of this study was to determine whether analysis of
apoptotic and cell cycle regulatory proteins could provide
information about the behaviour of poor prognostic breast
cancers, particularly in relation to the type of therapy used.
Induction of apoptosis and decreased proliferation are factors
in the biological response of breast cancer to chemotherapy
and endocrine therapy (Dowsett et al, 1999) and, therefore,
defects in their regulatory machinery could relate to poor
Table 2 Correlation between p53, cell cycle and apoptotic proteins
(+¼positive;  ¼negative)
Marker v marker P-value
p53 + bcl-2   0.005
phospho p53 + bcl-2   0.004
p53 + survivin + o0.0001
Phospho 53 + survivin + o0.0001
p53 + XIAP + 0.02
Phospho p53 + p21
waf1   0.033
ChK2 + survivin + 0.003
bcl-2   survivin + 0.001
ChK2¼checkpoint kinase 2
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such as p53, bcl-2, bax and p21, the phosphorylation status of p53,
Chk2 and the IAP family members survivin and XIAP were
considered.
The patients had all died of breast cancer, were of a lower
median age (National Institutes of Health Consensus Development
Panel, 2001), with a high frequency of T2 and above, node positive,
grade III cancers. They therefore differ from many early stage
breast cancer patients but are still an important clinical group and
can provide information of relevance to other breast cancer
patients.
The most significant finding related to the IAP protein, survivin.
The presence of survivin had a highly significant relationship with
shorter duration of survival in both univariate and multivariate
analysis, particularly for the neoadjuvant therapy and adjuvant
chemotherapy plus hormonal therapy groups. A previous study
by Span et al (2004), which measured Survivin mRNA, found
expression to be an independent marker of relapse free and overall
survival although another examining mRNA did not (O’Driscoll
et al, 2003). Span et al (2004) found similar relationships between
survivin, grade III and lack of ER. A recent report in which
enzyme-linked immunosorbent assay was used to measure
survivin found high levels to relate to poorer outcome, which
was independent of other factors (Ryan et al, 2006). However, two
immunohistochemical studies report different findings to the
present one. Tanaka et al (2000) found no relationship between
survivin and p53 or ER, but a positive correlation with bcl-2 and
reduced apoptotic index. The latter correlated to survival but
survivin did not. A different antibody was used which only gave
cytoplasmic reactivity. The numbers studied were similar with
many being T2 and 61% node positive. Kennedy et al (2003) used
the same antibody (AB469) as the present study but found a
correlation between presence of Survivin and better prognosis.
They evaluated nuclear and cytoplasmic reactivity separately and
found nuclear staining to be associated with better outcome,
whereas cytoplasmic staining was not significant. We found that
the majority of tumours that expressed survivin had a combined
pattern of reactivity and therefore did not undertake separate
analysis. In some tumours, survivin was only observed in cells
undergoing mitosis. The ratio of detection of cytoplasmic to
nuclear reactivity can vary depending on the antibodies used
(Fortugno et al, 2001). A recent review of the significance of
survivin in cancers generally (Li et al, 2005) identified more
studies in which it was found to relate to poorer prognosis, and
recommended that for technical reasons nuclear and cytoplasmic
staining should not be considered separately, the approach used in
the present study.
Although survivin was originally considered to be an inhi-
bitor of apoptosis (Deveraux and Reed, 1999) it has now been
implicated in cell proliferation, having functions at cell division
to control microtubule stability and mitotic spindle assembly
(Fortugno et al, 2001; Giodini et al, 2002; Beardsmore et al, 2004).
Our findings that there was no relationship between survivin and
apoptosis and an inverse relationship with the anti-apoptotic
protein bcl-2, plus a correlation with high grade and high
proliferation indicates that the function of survivin within the
carcinomas studied relates to its role in cell proliferation rather
than apoptosis.
A possible correlation between expression of HER-2 and
survivin has been reported (Asanuma et al, 2005) but was not
found in the present study. The frequency of HER-2-positive cases
was quite different, 66% compared to 25% in the present study that
would be expected for such a patient group, which may explain the
difference in relationships.
Immunohistochemical evaluation of p53 was of no value. There
are several problems in using this technique for p53 that relate to a
failure to detect all mutations plus assessment of what is positive
(Hall and McCluggage, 2006) so the available evidence would
favour the use of mutational analysis (Bergh et al, 1995; Aas et al,
1996; Berns et al, 2000). Phosphorylation of p53 at Ser
392 has been
shown to be a frequent modification in tumours (Minamoto et al,
2001). The biological role of ser
392 phosphorylation of wild-type
p53 is unclear, but it may regulate the oncogenic function of
mutant p53 (Yap et al, 2004). Immunohistochemical detection of
phosphorylated Ser
392 is more frequent in breast cancers with
mutant rather than wild-type p53 (Nenutil et al, 2005). In other
tumours the presence of p53 phosphorylated at Ser
392 has been
associated with poorer survival (Matsumoto et al, 2004). In this
series its presence related to a shorter duration of survival,
particularly for those patients receiving adjuvant hormonal
therapy. It is recognised that TP53 mutations can predict poor
response to tamoxifen (Berns et al, 2000). Phosphorylation of Ser
15
has also been detected in breast cancers with mutant p53 (Nenutil
et al, 2005) and would merit further analysis.
Reduced expression of ChK2 has been reported in breast cancer
with and without mutations (Sullivan et al, 2002; Kilpivaara et al,
2005), with similar correlations to tumour characteristics as in the
present study, but with no relationship to survival. Mutation status
may be more important as a marker of predisposition than protein
loss and tumour behaviour.
The findings for bcl-2 are similar to those reported by others
(Gee et al, 1994; Daidone et al, 1999a) with correlations to better
grade, presence of ER and longer survival. Unlike others
(Krajewski et al, 1995) bax did not contribute. The presence of
p21 was associated with markers of a better prognosis and longer
duration of survival for those receiving adjuvant hormonal
therapy, which differs from that of Caffo et al (1996), who found
it to be associated with shorter duration of survival, whereas
Gohring et al (2001) found no relationship. Oestrogen receptor
related to longer duration of survival but this was for the group
receiving hormonal therapy, emphasising that any impact it has on
survival relates to its value as a predictive marker of response. The
study also demonstrates that grade, when carefully performed
following guidelines, is an important independent prognostic
indicator of value for all breast cancers.
In conclusion, the inhibitor of apoptosis protein survivin is a
highly significant predictor of shorter duration of survival in
patients with poor prognostic breast cancer and merits evaluation
in a wider group of patients.
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Table 3 Cox regression analysis of factors in relation to duration of
survival
B SE Wald Sig
p53 phos 0.0018 0.309 0.003 0.953
MIB1 0.134 0.294 0.201 0.649
bcl-2 0.338 0.296 1.305 0.253
Survivin 0.693 0.248 7.827 0.005
Grade 1.477 0.397 13.845 0.000
Size 0.228 0.160 2.037 0.153
ER 0.014 0.408 0.001 0.974
ER¼oestrogen receptor
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